Clinical implications of drug–drug interactions with P2Y12 receptor inhibitors
Open Access
- 9 January 2014
- journal article
- review article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 12 (1), 2-13
- https://doi.org/10.1111/jth.12445
Abstract
No abstract availableThis publication has 77 references indexed in Scilit:
- The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel responsePharmacogenetics and Genomics, 2013
- Effects ofCYP2C19Genotype on Outcomes of Clopidogrel TreatmentThe New England Journal of Medicine, 2010
- Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitroBritish Journal of Pharmacology, 2010
- Impact of Cytochrome P450 2C19 Loss-of-Function Polymorphism and of Major Demographic Characteristics on Residual Platelet Function After Loading and Maintenance Treatment With Clopidogrel in Patients Undergoing Elective Coronary Stent PlacementJournal of the American College of Cardiology, 2010
- Membrane transporters in drug developmentNature Reviews Drug Discovery, 2010
- Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseasesBritish Journal of Pharmacology, 2010
- Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel TherapyJama-Journal Of The American Medical Association, 2009
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelThe New England Journal of Medicine, 2009
- Genetic Determinants of Response to Clopidogrel and Cardiovascular EventsThe New England Journal of Medicine, 2009
- A multiple dose study of prasugrel (CS‐747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humansBritish Journal of Clinical Pharmacology, 2006